We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia.
- Authors
Del Rosario García, Betel; Viña Romero, María Micaela; González Rosa, Virginia; Alarcón Payer, Carolina; Oliva Oliva, Leonor; Merino Alonso, Francisco Javier; Nazco Casariego, Gloria Julia; Gutiérrez Nicolás, Fernando
- Abstract
Objective: Tyrosine kinase inhibitors (TKIs) have successfully changed the natural course of chronic myeloid leukaemia (CML). Although they are highly effective drugs, their clinical benefit is conditioned by adherence. This study aims to analyse the adherence of CML patients treated with TKIs and to identify the main factors influencing their adherence to TKIs treatment. Material and methods: An 8-month prospective, observational, multicentre study which included patients diagnosed with CML on treatment with TKIs attending the outpatient departments (OPD) of the Pharmacy Services of the participating hospitals. Adherence was assessed using two methods: the Simplified Medication Adherence Questionnaire (SMAQ) and the register of treatment dispensations from the OPDs. To analyse the predictors of adherence, a questionnaire was developed to report demographic and socio-economic information on the patients. Results: A total of 130 patients enrolled in this study. Adherence rate was 56.9% (n = 74) among individuals, not conditioned by the type of drug used: imatinib (54.8%), nilotinib (63.6%) or dasatinib (54.3%) (p = 0.67). The patient educational level (p = 0.047) and employment status (p = 0.028) were predictors of non-adherence to treatment. Conclusions: Adherence is one of the most relevant parameters affecting the effectiveness of highly effective chronic treatments. Approximately half of our patients showed inadequate adherence to treatment with TKIs, with employment status and the individual's level of education emerging as the determining factors.
- Subjects
THERAPEUTIC use of antineoplastic agents; PATIENT compliance; RISK assessment; OUTPATIENT services in hospitals; PROTEIN-tyrosine kinase inhibitors; SCIENTIFIC observation; SOCIOECONOMIC factors; INDEPENDENT variables; QUESTIONNAIRES; LOGISTIC regression analysis; CHRONIC myeloid leukemia; CANCER patients; DESCRIPTIVE statistics; LONGITUDINAL method; DASATINIB; RESEARCH; DRUGS; SOCIODEMOGRAPHIC factors; IMATINIB; NILOTINIB; DATA analysis software; HOSPITAL pharmacies; EDUCATIONAL attainment; EMPLOYMENT
- Publication
Journal of Oncology Pharmacy Practice, 2024, Vol 30, Issue 5, p902
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552231196130